Since the 1980s patients with spinal dysraphism have had aggressive bladder management with clean intermittent catheterisation and anticholinergic therapy from early on in life. This strategy aims at improving lower and therefore upper urinary tract function thus decreasing the risk...
Tubeless percutaneous nephrolithotomy (PCNL) is increasingly being used in carefully selected patients to reduce hospital stay and analgesia requirements, especially in those with little bleeding who become stone free or have insignificant residual fragments (usually <4mm). Various agents have been...
There is currently a trend towards robot-assisted laparoscopic radical prostatectomy (RALP) as opposed to open radical prostatectomy (ORP) despite ongoing debates about oncological outcomes in patients treated for prostate cancer (PCa). Several papers have compared both surgical approaches but available...
The Urology Foundation (TUF) has appointed Rebecca Porta as Chief Executive. An established and experienced charity Chief Executive, Rebecca brings a wealth of experience having held senior roles within some of the UK’s leading health and medical research charities.
Sarcomatoid differentiation is a rare variant of urothelial carcinoma (UC) seen in 0.6% of cases. Its response to neo-adjuvant chemotherapy (NAC) has not been well reported. The authors have done a retrospective analysis of patients undergoing cystectomy between 1995 and...
A study focused on stereotactic ablative radiotherapy (SAbR) as a treatment for primary renal cell carcinoma (RCC) has yielded significant findings. The primary objective of the study was successfully met, demonstrating a 94% local control rate at one year among...
As our patients with spina bifida (SB) continue to live longer into adulthood we recognise that many of these men experience challenges with sexual health, related to their underlying neurological function. Few studies on male sexual health in this population...
Incontinence poses a substantial economic burden on the UK’s NHS, estimated at £536 million in 1999/2000, equivalent to approximately 1.1% of the total NHS spend, for both men and women. Over two decades later, this cost is expected to have...
Read all about it... It can be awkward when a patient asks you about a report in their favourite tabloid detailing an amazing research breakthrough or a ‘cutting-edge’ new treatment / test and you don’t know what they are talking...
Read all about it... It can be awkward when a patient asks you about a report in their favourite tabloid detailing an amazing research breakthrough or a ‘cutting-edge’ new treatment / test and you don’t know what they are talking...